Phuturdex › Drugs › Fluorodopa F 18
Drugs in development · updated 10 November 2026
Fluorodopa F 18: clinical trials and development status
Other names and codes: 18F-FDOPA
As of 10 November 2026 Fluorodopa F 18 is in 8 active clinical trials (recruiting or ongoing, phases I–III) for 17 diseases. The most advanced phase is III.
Summary updated every week · data as of 10 November 2026. In Phuturdex you can follow Fluorodopa F 18 and get an email at every change or safety alert.
Sign in free →Approved uses in the United States (FDA)
Fluorodopa F 18 Injection is indicated for use in positron emission tomography (PET) to visualize dopaminergic nerve terminals in the striatum for the evaluation of adult patients with suspected Parkinsonian syndromes (PS). Fluorodopa F 18 PET is an adjunct to other diagnostic evaluations. […]
Official documents
- Fluorodopa F18: FDA label (DailyMed) · FDA version of 15 January 2021
Use, doses, side effects and interactions: only these official documents are authoritative.
Diseases studied
For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov.
| Disease | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| Brain Neoplasms | III | 2 | NCT04706910 |
| Congenital hyperinsulinism | III | 2 | NCT04706910 |
| Parkinson's disease | III | 2 | NCT04706910 |
| Lewy body dementia | III | 1 | NCT04706910 |
| Neuroblastoma | III | 1 | NCT04706910 |
| Neuroendocrine tumor | III | 1 | NCT04706910 |
| Stroke | III | 1 | NCT03998852 |
| Cushing's syndrome | II | 1 | NCT02019706 |
| Glioblastoma | II | 1 | NCT05781321 |
| Glioma | II | 1 | NCT07542158 |
| Neoplasm | II | 1 | NCT07542158 |
| Parkinsonian Disorders | II | 1 | NCT07542158 |
| Hyperinsulinism | I | 1 | NCT02021604 |
| Hypoglycemia | I | 1 | NCT02021604 |
| Insulinoma | I | 1 | NCT02021604 |
| Multiple system atrophy | I | 1 | NCT04246437 |
| Pure autonomic failure | I | 1 | NCT04246437 |
Sites in Europe
1 sites of the active trials in 1 European countries, 1 recruiting.
- France1
Sites declared by the sponsors on ClinicalTrials.gov; region worked out by Phuturdex from the geographic point. The list of sites with city and recruitment status is in the app. See the sites →
Everything on Fluorodopa F 18
In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.
Open in Phuturdex →Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 10 November 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.